1. Home
  2. NEPH vs EVAX Comparison

NEPH vs EVAX Comparison

Compare NEPH & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$3.65

Market Cap

37.7M

Sector

Health Care

ML Signal

HOLD

EVAX

Evaxion Biotech

N/A

Current Price

$4.00

Market Cap

32.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEPH
EVAX
Founded
1997
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.7M
32.7M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
NEPH
EVAX
Price
$3.65
$4.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$11.67
AVG Volume (30 Days)
32.6K
27.0K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
1000.00
N/A
EPS
0.01
N/A
Revenue
$18,789,000.00
N/A
Revenue This Year
$11.24
N/A
Revenue Next Year
$11.58
$328.20
P/E Ratio
$369.50
N/A
Revenue Growth
32.67
N/A
52 Week Low
$2.66
$2.11
52 Week High
$6.42
$12.15

Technical Indicators

Market Signals
Indicator
NEPH
EVAX
Relative Strength Index (RSI) 57.72 47.58
Support Level $3.64 $3.93
Resistance Level $3.78 $4.65
Average True Range (ATR) 0.28 0.19
MACD 0.03 -0.02
Stochastic Oscillator 85.23 28.98

Price Performance

Historical Comparison
NEPH
EVAX

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: